To probe this hypothesis, two markers (cluster of differentiation 44; CD44,[37] cluster of differentiation 133; CD133[38, 39]) were investigated that are positively associated with drug resistance in breast cancer cells. This evidence concerns the gene PROM1 and breast carcinoma.